The White House issued a new Section 232 proclamation establishing a tariff framework for patented pharmaceuticals and associated ingredients. The action links duty exposure to patent status, country of origin, and company participation in onshoring and pricing agreements. The structure is targeted, conditional, and designed to differentiate between patented and generic products while incentivizing domestic production.
WHAT PRODUCTS ARE SUBJECT TO THE NEW SECTION 232 PHARMACEUTICAL TARIFFS
The tariffs apply to patented pharmaceutical products and their associated active pharmaceutical ingredients and key starting materials, as defined under new HTSUS Chapter 99 provisions. Patent status is central to scope. Products subject to a valid, unexpired U.S. patent and listed in FDA reference frameworks such as the Orange Book and Purple Book fall within coverage, along with their associated ingredients.
Generic pharmaceuticals, biosimilars, and their inputs are not subject to tariffs at this time.
HOW DOES THE TARIFF STRUCTURE WORK IN PRACTICE?
The framework introduces a tiered duty model:
- 100 percent duty applies as the default rate for covered patented products
- 20 percent duty applies to companies with approved onshoring plans, increasing to 100 percent after April 2, 2030
- 0 percent duty applies to companies that meet both onshoring requirements and Most-Favored-Nation pricing agreement criteria through January 20, 2029
- 15 percent duty applies to products from designated trade partners, including the European Union, Japan, South Korea, Switzerland, and Liechtenstein
- A reduced rate applies to products of the United Kingdom, subject to future agreement implementation
Where multiple provisions apply, the lowest applicable duty rate governs. This creates a compliance-driven tariff structure where duty exposure depends on company actions, not just product classification.
HOW DO ONSHORING AND MFN AGREEMENTS IMPACT DUTY OUTCOMES?
Tariff relief is directly tied to participation in two mechanisms: onshoring plans approved by the Department of Commerce, and Most-Favored-Nation pricing agreements coordinated with the Department of Health and Human Services. Companies that meet both criteria may qualify for temporary zero-duty treatment. Those that only meet onshoring requirements receive a reduced rate that escalates over time. The framework includes monitoring, reporting, and audit requirements. Tariffs may be increased or reapplied if commitments are not met.
CLICK TO READ THE FACT SHEET: https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/
WHEN DO THE NEW TARIFFS TAKE EFFECT?
Implementation is phased:
- July 31, 2026, for companies listed in Annex III
- September 29, 2026, for all other covered companies
These phases align with the 120-day and 180-day rollout timelines outlined in the proclamation.
REVIEW THE MODIFICATIONS TO THE HTSUS HERE: https://www.whitehouse.gov/wp-content/uploads/2026/04/Pharmaceuticals-Imports-ANNEXES-I-II-III-IV.pdf
WHAT CHANGES FOR IMPORTERS UNDER THIS FRAMEWORK
This action shifts pharmaceutical import compliance beyond standard classification and valuation.
Importers must now evaluate:
- Patent status and FDA listing
- Country of origin
- Company-specific agreement eligibility
- Alignment with onshoring and pricing requirements
Foreign Trade Zone treatment is also impacted. Covered goods admitted after the effective date must enter under privileged foreign status, locking in duty exposure at the time of admission. Contact a trusted Customs broker like if you have questions about how these changes may impact your supply chain.
Stay up-to-date on freight news with Green’s Weekly Freight Market Update by following us on LinkedIn. For continuous updates, make sure to check out our website at greenworldwide.com.
